Study to Evaluate the Efficacy and Safety of CKD-352
NCT04548427
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
283
Enrollment
INDUSTRY
Sponsor class
Conditions
Dry Eye Disease
Interventions
DRUG:
CKD-352
DRUG:
Diquafosol Sodium 3%
Sponsor
Chong Kun Dang Pharmaceutical